UBS Maintains Buy on Merck & Co, Raises Price Target to $148
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow maintains a Buy rating on Merck & Co (NYSE:MRK) and raises the price target from $135 to $148.
February 02, 2024 | 6:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Colin Bristow maintains a Buy rating on Merck & Co and raises the price target from $135 to $148.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100